Baudax Bio Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq rise as soft inflation data, bank earnings buoy sentiment
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Baudax Bio (BXRX) Misses Q2 EPS by $1.07
August 10, 2020 7:18 AM EDTBaudax Bio (NASDAQ: BXRX) reported Q2 EPS of ($1.72), $1.07 worse than the analyst estimate of ($0.65).
The second quarter of 2020 was most important because of the full commercial launch of ANJESO, said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. We believe that with... More
